A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer

Trial Profile

A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2015

At a glance

  • Drugs Docetaxel (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TRAIL
  • Most Recent Events

    • 13 Jul 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 20 Apr 2015 Status changed from recruiting to completed.
    • 30 Jan 2013 Planned number of patients changed from 562 to 276 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top